Adiponectin, Leptin, h-CRP Values in Obese Children - Important Markers for Metabolic Syndrome? (ChildObes)

Obesity is a chronic inflammatory disorder in which leptin, adiponectin and C reactive protein (CRP) play an important role. This study aimed to investigate the relationship between markers of adiposity like leptin, adiponectin and high sensitive C reactive protein (hsCRP) in obese children, and to determine whether these adipokines are significant markers in defining metabolic syndrome in pediatric population

Study Overview

• Status: Completed
• Conditions: Obesity, Metabolically Benign
• Intervention / Treatment: Other: MetS+; Other: MetS-

Detailed Description

The idea that adipose tissue is just a form of energy storage has changed dramatically in recent years. Currently, adipose tissue is considered to be a true endocrine gland that fulfills multiple roles in regulating different biological functions. Communication between adipose tissue and the rest of the systems is accomplished through bioactive mediators (adipokines) Adipokines control energy homeostasis and are involved in metabolic, endocrine and immunological processes.This study aimed to investigate the relationship between markers of adiposity like leptin, adiponectin and high sensitive C reactive protein (hsCRP) in obese children, and to determine whether these adipokines are significant markers in defining metabolic syndrome in pediatric population.The current retrospective observational study was conducted at the "Louis Turcanu" Emergency Hospital Timisoara over a period of one year, from July 2013 and June 2014. All inborn patient files were analyzed as anonymised limited data sets from archived records of the Endocrinology, Diabetology and Cardiology department.

• Study Type: Observational
• Enrollment (Actual): 122

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 4 years to 18 years (ADULT, CHILD)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

• Sampling Method: Probability Sample

Study Population

All children admitted to the Endocrinology, Diabetology and Cardiology Department who met the Inclusion Criteria

Description

Inclusion Criteria:

• obese children (BMI> 95th percentile)

Exclusion Criteria:

• obesity caused by endocrine disease, syndromic obesity, systemic disease or acute illness.

Study Plan

How is the study designed?

Number of groups / cohorts

2

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
MetS+; Obese group with metabolic syndrome/Data processing from Patient Medical Files	Other: MetS+; Data processing from Patient Medical Files
MetS-; Obese group without metabolic syndrome/Data processing from Patient Medical Files	Other: MetS-; Data processing from Patient Medical Files

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Defining obesity in the pediatric population	Measuring weight in kilograms and height in meters in order to calculate BMI and represent it on the percentile graph.	Weight and height were measured on day 1 of admission. Obesity was defined as a BMI > the 95th percentile.
Leptin changes in the obese children with metabolic syndrome	Evaluating leptin in the obese group with metabolic syndrome	Leptin levels were measured on day 1 of admission. Normal range was considered < 24ng/ml.
Adiponectin changes in the obese children with metabolic syndrome	Evaluating adiponectin in the obese group with metabolic syndrome	Adiponectin levels were measured on day 1 of admittance in children aged between 4 and18 years. Levels 4-26 mcg/ml were defined as normal values.
Assessing cardiovascular risk in the obese children with metabolic syndrome	Evaluating hsCRP in the obese group with metabolic syndrome	hsCRP levels were measured on day 1 of admittance in children aged between 4 and 18 years. Normal levels were considered between 0.1-2.8 mg/l

Collaborators and Investigators

• Sponsor: Alexandru Florin Rogobete
• Collaborators: University of Medicine and Pharmacy "Victor Babes" Timisoara

Publications and helpful links

General Publications

• Beyazit F, Unsal MA. Obesity and insulin resistance are significant predictors of serum leptin levels. J Turk Ger Gynecol Assoc. 2017 Sep 1;18(3):158-159. doi: 10.4274/jtgga.2017.0027. No abstract available.
• Lopez-Quintero A, Garcia-Zapien AG, Flores-Martinez SE, Diaz-Burke Y, Gonzalez-Sandoval CE, Lopez-Roa RI, Medina-Diaz E, Munoz-Almaguer ML, Sanchez-Corona J. Contribution of polymorphisms in the LEP, LEPR and RETN genes on serum leptin and resistin levels in young adults from Mexico. Cell Mol Biol (Noisy-le-grand). 2017 Aug 30;63(8):10-18. doi: 10.14715/cmb/2017.63.8.3.
• Bagherniya M, Khayyatzadeh SS, Heidari Bakavoli AR, Ferns GA, Ebrahimi M, Safarian M, Nematy M, Ghayour-Mobarhan M. Serum high-sensitive C-reactive protein is associated with dietary intakes in diabetic patients with and without hypertension: a cross-sectional study. Ann Clin Biochem. 2018 Jul;55(4):422-429. doi: 10.1177/0004563217733286. Epub 2017 Nov 23.

Study record dates

Study Major Dates

• Study Start (ACTUAL): March 11, 2016
• Primary Completion (ACTUAL): August 11, 2017
• Study Completion (ACTUAL): September 10, 2017

Study Registration Dates

• First Submitted: September 12, 2017
• First Submitted That Met QC Criteria: November 26, 2017
• First Posted (ACTUAL): November 28, 2017

Study Record Updates

• Last Update Posted (ACTUAL): November 28, 2017
• Last Update Submitted That Met QC Criteria: November 26, 2017
• Last Verified: November 1, 2017

More Information

Terms related to this study

• Keywords: adipokines, metabolic syndrome, obese children
• Additional Relevant MeSH Terms: Glucose Metabolism Disorders; Metabolic Diseases; Overnutrition; Nutrition Disorders; Overweight; Body Weight; Insulin Resistance; Hyperinsulinism; Obesity; Metabolic Syndrome; Obesity, Metabolically Benign
• Other Study ID Numbers: 12870

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No